.png){kind=icon}
.png){kind=icon}
Return
Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study
.png){kind=icon}
OA
AI
M
E
K
H
A
M
A
A
N
A
B
L
A
J
S
A
A
R
A
H
M
S
DOI：10.1002/cncr.70524.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
No large, randomized trials have compared three or more tyrosine kinase inhibitors (TKIs) in a single chronic myeloid leukemia (CML) cohort. Most studies are two-arm comparisons versus imatinib, or rely on indirect methods.
Keywords:
BCR-ABL1 kinetics
chronic myeloid leukemia
event-free survival
overall survival
tyrosine kinase inhibitors
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
5.1
Papers:
2.0W
Citations:
6.2W
Organization
Cited Papers